Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today

By Robert Lakin, InvestorPlace Contributor

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket trading.

Cannabis Stocks: Why TLRY, CGC, APHA, ACB and SNDL Are Climbing Today

By Robert Lakin, InvestorPlace Contributor

Cannabis stocks like SNDL, CGC and TLRY stock are on the move Monday after Tilray announced a medical marijuana distribution deal.

ZOM Stock: Why Red-Hot Zomedica Shares Are on the Move Today

By Robert Lakin, InvestorPlace Contributor

Zomedica's massive rally could be cooling off. A discounted secondary offering may have halted ZOM stock's double-digit gains in their tracks.

OCGN Stock: Why Ocugen Shares Are Rocketing Higher Again Today

By Robert Lakin, InvestorPlace Contributor

Shares of Ocugen continue on February's rollercoaster ride. OCGN stock was up more than 60% on news of a premium-priced private placement.

PLTR Stock: Why Red-Hot Palantir Is on the Move Today

By Robert Lakin, InvestorPlace Contributor

Palantir Technologies will team up with IBM to expand its sales and support, particularly in artificial intelligence software. PLTR stock is up in Monday's premarket trading.

Load More